Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART (CLEAR)

This study has been completed.
Sponsor:
Collaborators:
Massachusetts General Hospital
Monash University
University of Sydney
Novartis
Aarhus University Hospital
Information provided by (Responsible Party):
University of Aarhus
ClinicalTrials.gov Identifier:
NCT01680094
First received: September 3, 2012
Last updated: February 24, 2014
Last verified: February 2014